1 | observation | 6,893 |
2 | non-closure | 37 |
3 | audiogram | 30 |
4 | nonprogression | 19 |
5 | nonclosure | 18 |
6 | nonresurfacing | 17 |
7 | pau | 17 |
8 | 8-gy | 11 |
9 | occ-walk | 11 |
10 | off-therapy | 11 |
11 | drug-treatment | 10 |
12 | recoupling | 10 |
13 | ro5093151 | 10 |
14 | non-disclosure | 9 |
15 | as15 | 8 |
16 | aspirin-placebo | 8 |
17 | renormalization | 8 |
18 | bp-limb | 7 |
19 | cdmard | 7 |
20 | needle-retaining | 7 |
21 | post-guideline | 7 |
22 | allotransplant | 6 |
23 | g-60 | 6 |
24 | observation-only | 6 |
25 | pazopanib/pemetrexed | 6 |
26 | ns-spb | 5 |
27 | periinduction | 5 |
28 | post-9/11 | 5 |
29 | unresurfaced | 5 |
30 | 3nrti | 4 |
31 | non-pms | 4 |
32 | om-8930 | 4 |
33 | order-managed | 4 |
34 | treatment/observation | 4 |
35 | 78-gy | 3 |
36 | astograph | 3 |
37 | control-diet | 3 |
38 | depistage | 3 |
39 | high-training | 3 |
40 | lights-on | 3 |
41 | low-training | 3 |
42 | non-withdrawal | 3 |
43 | p-adhesin | 3 |
44 | phy-3 | 3 |
45 | post-ejaculatory | 3 |
46 | post-teriparatide | 3 |
47 | pre-mlp | 3 |
48 | predetailing | 3 |
49 | unilaterality | 3 |
50 | 14-3-3γ/p-β-catenin | 2 |
51 | 1966-1969 | 2 |
52 | 1980-1986 | 2 |
53 | benzopyrans | 2 |
54 | costs/healthy | 2 |
55 | fasting/post-absorptive | 2 |
56 | group/time | 2 |
57 | hypokalemic-hypomagnesemic | 2 |
58 | indwell | 2 |
59 | last-observation | 2 |
60 | led-curing | 2 |
61 | miligrams | 2 |
62 | multi-dosage | 2 |
63 | nonblinding | 2 |
64 | perioperatory | 2 |
65 | pftg | 2 |
66 | post-funding | 2 |
67 | pre-lunch | 2 |
68 | resource-enhancing | 2 |
69 | self-narratives | 2 |
70 | srl+st | 2 |
71 | tld-700 | 2 |
72 | toddler-preschool | 2 |
73 | trans-operative | 2 |
74 | 'cortisol'×'testosterone'×'experimental | 1 |
75 | 'equivalent | 1 |
76 | 0.0748 | 1 |
77 | 105-day | 1 |
78 | 11-mo | 1 |
79 | 11.3-year | 1 |
80 | 15.6-month | 1 |
81 | 38-day | 1 |
82 | 66-month | 1 |
83 | 8.25-year | 1 |
84 | 8year | 1 |
85 | beta-hydroxysteroid-dehydrogenase | 1 |
86 | chemoradiation-surgery | 1 |
87 | chemotherapy-surgery | 1 |
88 | d2-reached | 1 |
89 | da-adduct | 1 |
90 | difference=6.7 | 1 |
91 | difference=7.3 | 1 |
92 | ejection/ejection | 1 |
93 | end-of-the-treatment | 1 |
94 | esl+oc/oc | 1 |
95 | ever-shorter | 1 |
96 | follow-up.drug | 1 |
97 | greatest-risk | 1 |
98 | hospital/satellite | 1 |
99 | incp | 1 |
100 | light-avoidance | 1 |
101 | lumberjack | 1 |
102 | naofukang | 1 |
103 | normotensive-hypertrophic | 1 |
104 | peri-intervention | 1 |
105 | peri-operational | 1 |
106 | pre-han | 1 |
107 | preparathyroidectomy | 1 |
108 | preratings | 1 |
109 | regenerative-dose | 1 |
110 | studieswas | 1 |
111 | therapy-modification | 1 |
112 | unpressed | 1 |
113 | variable*intervention | 1 |
114 | virus-shedding | 1 |
115 | whi-e | 1 |
1 | 'cortisol'×'testosterone'×'experimental | 1 |
2 | 'equivalent | 1 |
3 | 0.0748 | 1 |
4 | 105-day | 1 |
5 | 11-mo | 1 |
6 | 11.3-year | 1 |
7 | 14-3-3γ/p-β-catenin | 2 |
8 | 15.6-month | 1 |
9 | 1966-1969 | 2 |
10 | 1980-1986 | 2 |
11 | 38-day | 1 |
12 | 3nrti | 4 |
13 | 66-month | 1 |
14 | 78-gy | 3 |
15 | 8-gy | 11 |
16 | 8.25-year | 1 |
17 | 8year | 1 |
18 | allotransplant | 6 |
19 | as15 | 8 |
20 | aspirin-placebo | 8 |
21 | astograph | 3 |
22 | audiogram | 30 |
23 | benzopyrans | 2 |
24 | beta-hydroxysteroid-dehydrogenase | 1 |
25 | bp-limb | 7 |
26 | cdmard | 7 |
27 | chemoradiation-surgery | 1 |
28 | chemotherapy-surgery | 1 |
29 | control-diet | 3 |
30 | costs/healthy | 2 |
31 | d2-reached | 1 |
32 | da-adduct | 1 |
33 | depistage | 3 |
34 | difference=6.7 | 1 |
35 | difference=7.3 | 1 |
36 | drug-treatment | 10 |
37 | ejection/ejection | 1 |
38 | end-of-the-treatment | 1 |
39 | esl+oc/oc | 1 |
40 | ever-shorter | 1 |
41 | fasting/post-absorptive | 2 |
42 | follow-up.drug | 1 |
43 | g-60 | 6 |
44 | greatest-risk | 1 |
45 | group/time | 2 |
46 | high-training | 3 |
47 | hospital/satellite | 1 |
48 | hypokalemic-hypomagnesemic | 2 |
49 | incp | 1 |
50 | indwell | 2 |
51 | last-observation | 2 |
52 | led-curing | 2 |
53 | light-avoidance | 1 |
54 | lights-on | 3 |
55 | low-training | 3 |
56 | lumberjack | 1 |
57 | miligrams | 2 |
58 | multi-dosage | 2 |
59 | naofukang | 1 |
60 | needle-retaining | 7 |
61 | non-closure | 37 |
62 | non-disclosure | 9 |
63 | non-pms | 4 |
64 | non-withdrawal | 3 |
65 | nonblinding | 2 |
66 | nonclosure | 18 |
67 | nonprogression | 19 |
68 | nonresurfacing | 17 |
69 | normotensive-hypertrophic | 1 |
70 | ns-spb | 5 |
71 | observation | 6,893 |
72 | observation-only | 6 |
73 | occ-walk | 11 |
74 | off-therapy | 11 |
75 | om-8930 | 4 |
76 | order-managed | 4 |
77 | p-adhesin | 3 |
78 | pau | 17 |
79 | pazopanib/pemetrexed | 6 |
80 | peri-intervention | 1 |
81 | peri-operational | 1 |
82 | periinduction | 5 |
83 | perioperatory | 2 |
84 | pftg | 2 |
85 | phy-3 | 3 |
86 | post-9/11 | 5 |
87 | post-ejaculatory | 3 |
88 | post-funding | 2 |
89 | post-guideline | 7 |
90 | post-teriparatide | 3 |
91 | pre-han | 1 |
92 | pre-lunch | 2 |
93 | pre-mlp | 3 |
94 | predetailing | 3 |
95 | preparathyroidectomy | 1 |
96 | preratings | 1 |
97 | recoupling | 10 |
98 | regenerative-dose | 1 |
99 | renormalization | 8 |
100 | resource-enhancing | 2 |
101 | ro5093151 | 10 |
102 | self-narratives | 2 |
103 | srl+st | 2 |
104 | studieswas | 1 |
105 | therapy-modification | 1 |
106 | tld-700 | 2 |
107 | toddler-preschool | 2 |
108 | trans-operative | 2 |
109 | treatment/observation | 4 |
110 | unilaterality | 3 |
111 | unpressed | 1 |
112 | unresurfaced | 5 |
113 | variable*intervention | 1 |
114 | virus-shedding | 1 |
115 | whi-e | 1 |
1 | tld-700 | 2 |
2 | om-8930 | 4 |
3 | g-60 | 6 |
4 | post-9/11 | 5 |
5 | ro5093151 | 10 |
6 | phy-3 | 3 |
7 | difference=7.3 | 1 |
8 | as15 | 8 |
9 | 1980-1986 | 2 |
10 | difference=6.7 | 1 |
11 | 0.0748 | 1 |
12 | 1966-1969 | 2 |
13 | bp-limb | 7 |
14 | ns-spb | 5 |
15 | normotensive-hypertrophic | 1 |
16 | hypokalemic-hypomagnesemic | 2 |
17 | esl+oc/oc | 1 |
18 | unresurfaced | 5 |
19 | order-managed | 4 |
20 | d2-reached | 1 |
21 | unpressed | 1 |
22 | pazopanib/pemetrexed | 6 |
23 | cdmard | 7 |
24 | whi-e | 1 |
25 | light-avoidance | 1 |
26 | post-teriparatide | 3 |
27 | multi-dosage | 2 |
28 | depistage | 3 |
29 | group/time | 2 |
30 | post-guideline | 7 |
31 | non-closure | 37 |
32 | nonclosure | 18 |
33 | non-disclosure | 9 |
34 | beta-hydroxysteroid-dehydrogenase | 1 |
35 | regenerative-dose | 1 |
36 | hospital/satellite | 1 |
37 | trans-operative | 2 |
38 | fasting/post-absorptive | 2 |
39 | naofukang | 1 |
40 | nonresurfacing | 17 |
41 | resource-enhancing | 2 |
42 | virus-shedding | 1 |
43 | nonblinding | 2 |
44 | post-funding | 2 |
45 | predetailing | 3 |
46 | recoupling | 10 |
47 | high-training | 3 |
48 | low-training | 3 |
49 | needle-retaining | 7 |
50 | led-curing | 2 |
51 | pftg | 2 |
52 | follow-up.drug | 1 |
53 | pre-lunch | 2 |
54 | astograph | 3 |
55 | 15.6-month | 1 |
56 | 66-month | 1 |
57 | 3nrti | 4 |
58 | lumberjack | 1 |
59 | occ-walk | 11 |
60 | greatest-risk | 1 |
61 | peri-operational | 1 |
62 | 'cortisol'×'testosterone'×'experimental | 1 |
63 | non-withdrawal | 3 |
64 | indwell | 2 |
65 | toddler-preschool | 2 |
66 | audiogram | 30 |
67 | pre-han | 1 |
68 | 14-3-3γ/p-β-catenin | 2 |
69 | p-adhesin | 3 |
70 | lights-on | 3 |
71 | nonprogression | 19 |
72 | therapy-modification | 1 |
73 | observation | 6,893 |
74 | last-observation | 2 |
75 | treatment/observation | 4 |
76 | renormalization | 8 |
77 | ejection/ejection | 1 |
78 | periinduction | 5 |
79 | variable*intervention | 1 |
80 | peri-intervention | 1 |
81 | aspirin-placebo | 8 |
82 | 11-mo | 1 |
83 | incp | 1 |
84 | pre-mlp | 3 |
85 | 11.3-year | 1 |
86 | 8.25-year | 1 |
87 | 8year | 1 |
88 | ever-shorter | 1 |
89 | studieswas | 1 |
90 | self-narratives | 2 |
91 | preratings | 1 |
92 | miligrams | 2 |
93 | non-pms | 4 |
94 | benzopyrans | 2 |
95 | da-adduct | 1 |
96 | control-diet | 3 |
97 | allotransplant | 6 |
98 | 'equivalent | 1 |
99 | end-of-the-treatment | 1 |
100 | drug-treatment | 10 |
101 | srl+st | 2 |
102 | pau | 17 |
103 | 105-day | 1 |
104 | 38-day | 1 |
105 | 8-gy | 11 |
106 | 78-gy | 3 |
107 | costs/healthy | 2 |
108 | observation-only | 6 |
109 | preparathyroidectomy | 1 |
110 | off-therapy | 11 |
111 | chemoradiation-surgery | 1 |
112 | chemotherapy-surgery | 1 |
113 | post-ejaculatory | 3 |
114 | perioperatory | 2 |
115 | unilaterality | 3 |